Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Erbitux cetuximab: Phase II data

In the European Phase II (LUCAS) trial in 86 patients, 35% of 43 patients receiving Erbitux plus cisplatin and

Read the full 192 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE